Background/Aim: Accurate genotyping of CYP2D6 is challenging due to its inherent genetic variation, copy number variation (duplications and deletions) and hybrid formation with highly homologous pseudogenes. Because a relatively high percentage (~25%) of clinically prescribed drugs are substrates for this enzyme, accurate determination of its genotype for phenotype prediction is essential. Methods: A cohort of 365 patient samples was genotyped for CYP2D6 using Sanger sequencing (as the gold standard), hydrolysis probe assays or pyrosequencing. Results: A discrepant result between the three genotyping methods for the loss of function CYP2D6*3 (g.2549delA, rs35742686) genetic variant was found in one of the samples. This sample also contained the CYP2D6 g.2470T>C (rs17002852) variation, which had an allele frequency of 2.47% in our cohort. Redesign of the CYP2D6*3 pyrosequencing and hydrolysis probe assays to avoid CYP2D6 g.2470 corrected the anomaly. Conclusion: To evidence allele drop out and increase the accuracy of genotyping, intra-patient validation of the same genetic variation with at least two separate methods should be considered.
Cellular Physiology and Biochemistry
384-well format experiments were: 60°C for 30 sec., 95°C for 10 min., followed by 50 cycles of 92°C for 15 sec. and 60°C for 90 sec, and a final 30 sec. at 60°C. The two hydrolysis probe assays used in the 384-well format targeted CYP2D6*3 (g.2549delA, rs35742686); one was from Thermo (Assay ID C__32407232_50) and the other was custom designed and manufactured by Microsynth (Balgach, Switzerland). The sequences of the primers/probes from Thermo are proprietary. CYP2D6 copy number in each sample was assessed with two hydrolysis probe assays for the target gene (labeled with VIC): one within intron 2 (Hs.04083572_ cn) and the other within exon 9 (Hs.00010001_cn), in combination with one assay for the reference gene (labeled with FAM), RPPH1 (also known as RNAse P). 10mL reactions containing 1X Taqman® Universal PCR Master Mix no AmpErase® UNG, 1X target assay, 1X reference assay and 12ng gDNA were performed in MicroAmp® Optical 384-well Reaction Plates on the QuantStudio™ 12K Flex Real-Time PCR System (all from Thermo). Four technical replicates were performed for each sample for each target gene. Cycling parameters for copy number experiments were: 95°C for 10 min. followed by 40 cycles of 95°C for 15 sec. and 60°C for 1 min. CYP2D6 copy number quantification was performed with CopyCaller software Version 2.1 (Thermo) using default analysis settings.
Extra-long (XL) PCR
50mL XL-PCR reactions contained 1X JumpStart REDAccuTaq Long and Accurate (JS RAT LA) DNA Polymerase buffer (Sigma; St. Louis, MO), 1mM dNTPs (Thermo), 10% DMSO (Sigma), 0.8mM forward and reverse primers and 5 units JS RAT LA DNA Polymerase (Sigma). Primers and cycling parameters to amplify standard duplicated (no hybrid types) and standard non-duplicated CYP2D6 genes were described in [14] ; those used to determine the presence of CYP2D6/CYP2D7 and CYP2D7/CYP2D6 hybrids were described in [6] ; and those used to amplify CYP2D7 were described in [15] . CYP2D6 sequencing primers are shown (for all online suppl. material, see www.karger.com/doi/ 10.1159/000484380) in Suppl. Table 3 . Amplicons were visualized with either agarose gels or the QIAxcel Advanced XL automated gel electrophoresis system with the DNA screening cartridge (method AL420) (Qiagen) to confirm size and specificity. copy DNA (copy DNA) was purified with the QIAquick PCR Purification Kit (Qiagen) according to the manufacturer's instructions and quantified by spectrophotometry. copy DNA was commercially sequenced with the Sanger method (Microsynth).
Haplotype determination using allele specific PCR The primer sequences for allele specific PCRs are shown (see online suppl. material) in Suppl. Table 3 . Cycling parameters for fragment 1 were: 94°C for 20 sec., followed by 35 cycles of 94°C for 20 sec, 67.5°C for 30 sec and 68°C for 4 min. These were identical for fragment 2, except the annealing temperature was 61°C. Purification and sequencing were performed as described above.
Pyrosequencing
Pyrosequencing PCR and sequencing primers for CYP2D6*3 are shown in Table 2 . Reverse PCR primers were HPLC purified and biotinylated at their 5' end. copy DNA was generated with the PyroMark PCR kit (Qiagen). 25mL reactions contained 1X PyroMark PCR mastermix, 1X CoralLoad, 0.2mM forward and reverse primers and either 100ng gDNA or 10ng copy DNA. Cycling conditions were 95°C for 15 min. followed by 45 cycles of 94°C for 30 sec., 60°C for 30 sec., and 72°C for 30 sec., followed by a final extension step at 72°C for 10 min. Amplicons were visualized using the DNA screening cartridge (method AL420) on the QIAxcel Advanced XL automated gel electrophoresis system (Qiagen).
All pyrosequencing reagents, except for the streptavidin sepharose beads (GE Healthcare; Pfaffing, Austria), belonged to the PyroMark Q24 Advanced Reagents Kit (Qiagen). 15mL double-stranded copy DNA was bound to 1mL streptavidin sepharose beads in 40mL binding buffer. Beads carrying the double-stranded, biotinylated amplicons were captured on filter probes with aspiration. While maintaining aspiration, filter probes were immersed in 70% ethanol for 5 sec., denaturation buffer for 5 sec., and finally in 1X wash buffer for 10 sec. Single-stranded, biotinylated amplicons were released into wells containing 1mM sequencing primer in a total of 22mL annealing buffer and annealed for 5 min. at 80°C.
Pyrosequencing reactions were performed on the PyroMark Q24 Instrument (Qiagen) with the following dispensation order: TCAGCAGAT. dATP was provided as dATPaS in order to avoid interference with the luciferase enzyme. Pyrograms were analyzed with the PyroMark Analysis Software version 3.0.0 in allele quantification mode using default settings. 
Statistics
To determine departure from Hardy-Weinberg equilibrium, a chi-squared test with one degree of freedom was used where p < 0.05 was considered statistically significant.
Results
While genotyping a 365-sample cohort for CYP2D6 with both Sanger sequencing (as the gold standard) and a subset of hydrolysis probe assays (see online suppl. material, Suppl. Table 1 ), a discordant result concerning the CYP2D6*3 genetic variation was detected in sample #7. Specifically, Sanger sequencing showed that the sample was heterozygous at this position, whereas the hydrolysis probe assay from Thermo Fisher Scientific (Thermo) (assay ID C__32407232_50) showed that the sample was homozygous mutant for CYP2D6*3 ( Table 1) . As a first step to reconcile this disagreement and rule out whether an error was introduced by the polymerase used to generate the copy DNA for Sanger sequencing, we reamplified the CYP2D6 alleles from sample #7 and re-sequenced the region encompassing CYP2D6*3. The result matched that of the first Sanger sequencing outcome and showed again that the patient was heterozygous for CYP2D6*3.
We then compared the immediate 200 nucleotides upstream and downstream of the CYP2D6*3 position in ten other samples (that were either homozygous mutant or heterozygous for CYP2D6*3, and in which the results from the Thermo CYP2D6*3 hydrolysis probe assay and Sanger sequencing matched) with that of sample #7 and found that only sample #7 was heterozygous (T/C) for a genetic variation at g.2470 (rs17002852) ( Table 1) . While the exact sequences of the primers and probes from Thermo's hydrolysis probe assays are proprietary, CYP2D6 g.2470 is well within the plausible range for a CYP2D6*3 assay, and we hypothesized that this variation, if in trans with CYP2D6*3, might interfere with Thermo's hydrolysis probe assay. Allele Specific CYP2D6 Sequencing using g.843T>G Sanger sequencing revealed 26 heterozygous CYP2D6 variations from sample #7 (Fig.  1B) , and their rs numbers can be found in (see online suppl. material) Suppl. Table 2 . To determine how these 26 variations segregated between the two alleles, we developed allelespecific PCRs that exploited the heterozygous variation at position g.843. Forward and reverse primers were designed to specifically amplify the allele containing the CYP2D6 g.843T>G variation. One set was designed to amplify an ~2.8kb fragment from g.-1909 through g.843, and the other was designed to amplify an ~4kb fragment from g.843 through g.4751. PCR products of the expected size were detected in the positive control (homozygous mutant at g.843, GG) and sample #7 (heterozygous at g.843, TG), but not in the negative control (homozygous wild-type at g.843, TT) or the no template control (Fig. 1C) . The full CYP2D6 haplotypes of the positive and negative control are depicted (see online suppl. material) in Suppl. Fig. 1 . The allele specific PCRs only amplified CYP2D6, and not the upstream pseudogene CYP2D7, since no amplicon was generated in the negative control (which contains CYP2D7, data not shown), suggesting that the amplicons generated in sample #7 represent the CYP2D6 allele containing g.843T>G. After Sanger sequencing of both allele-specific PCR fragments, the variations found were subtracted from the unsegregated CYP2D6 genotype (Fig. 1B) , which revealed an allele-specific genotype of *3/*41 (Fig. 1D) . It is important to note that the g.2470T>C and CYP2D6*3 variations were in trans (on different alleles).
CYP2D6 g.2470T>C interferes with the CYP2D6*3 hydrolysis probe assay from Thermo
To determine whether the g.2470T>C variation interferes with Thermo's CYP2D6*3 hydrolysis probe assay, we designed a custom hydrolysis assay in which the amplification primers and probe did not overlap CYP2D6 g.2470. We then genotyped a sample set with both This CYP2D6*41 allele is also identical to that from sample #7.
As already mentioned, sample #7 (*3/*41) is heterozygous for both CYP2D6*3 and g.2470.
Some of these aforementioned samples were combined to generate additional genotypes (Fig. 2) . The genotyping results from these samples using the two hydrolysis probe assays are shown in Fig. 3A . Thermo's hydrolysis probe assay result for all samples was as expected, except for samples #6 and #7. Sample #7 (*3/*41, including g.2470T>C on the CYP2D6*41 allele) was erroneously called homozygous mutant for CYP2D6*3 and no signal was detected in sample #6, which is hemizygous for g.2470T>C. These data suggest that g.2470T>C prevents Thermo's hydrolysis probe assay from detecting the allele on which it is located. We analyzed the same set of samples with our custom CYP2D6*3 hydrolysis probe assay, in which the amplification primers or probe did not overlap g.2470. As shown in Fig. 3B , the CYP2D6*3 results for all samples matched the actual CYP2D6*3 genotype. The "no call" observed for sample #6, and the homozygous mutant CYP2D6*3 call observed for sample #7 using Thermo's hydrolysis probe assay were correctly reverted to homozygous wild type and heterozygous, respectively. These data also support the notion that g.2470T>C confers allele drop out with Thermo's CYP2D6*3 hydrolysis probe assay (Fig. 4) . homozygous wild type sample should theoretically result in an allelic quantification ratio of 100/0, where the numerator is the wild type nucleotide and the denominator is the mutant nucleotide. Accordingly, a heterozygous and homozygous mutant sample should have allelic quantification ratios of 50/50 and 0/100, respectively. After realizing that the g.2470T>C variation interferes with CYP2D6*3 hydrolysis probe genotyping assay, we scrutinized our current pyrosequencing assay for CYP2D6*3 obtained from that previously described by Langaee et. al [17] . Table 2 shows the pyrosequencing results from this CYP2D6*3 pyrosequencing assay in three CYP2D6*3 homozygous wild type, ten heterozygous and one homozygous mutant samples. In our hands, a small amplification bias towards the wild-type allele was observed, especially in the heterozygous samples. Of particular concern was the value obtained for sample #7, which is heterozygous for g.2470T>C variant. The allelic quantification value for this sample was 33/67 and biased towards the mutant allele, whereas all of the other heterozygous CYP2D6*3 sample values were biased towards the wild-type allele. Interestingly, the last nucleotide in the forward amplification primer of this pyrosequencing assay is complementary to CYP2D6 position g.2470. Therefore, we removed this nucleotide from the primer and re-ran the samples. As expected, the allelic quantification ratio for sample #7 changed from 33/67 to 65/35, the latter value of which was now similar with those obtained from the other heterozygous CYP2D6*3 samples. These data show that overlap of the forward amplification primer with g.2470 results in a strong amplification bias towards alleles that do not contain this variant. It should be noted that both of the CYP2D6*3 pyrosequencing assays amplify CYP2D7 (see online suppl. material, Suppl. Fig. 2) . Therefore, the pyrosequencing assay data presented in Table 2 was obtained from CYP2D6 copy DNA.
Frequency of g.2470T>C and loss of function CYP2D6 mutations
Direct transcription and translation of the CYP2D6 g.2470T>C variant would result in a synonymous amino acid substitution (p.His232=). The NCBI single nucleotide polymorphism (SNP) database currently lists the allele frequency of CYP2D6 g.2470T>C as 0.74% in the ExAc_Aggregated_Populations population. However, this value is likely underestimated, since the majority of CYP2D6 variant testing commonly only include variations with >1% allele frequency and/or functional relevant variants [18] . Indeed, we genotyped the CYP2D6 g.2470 position in 365 samples using Sanger sequencing and hydrolyis probe assays, and found that the variant allele had a frequency of 2.47%. The minor allele frequencies of the CYP2D6 loss of function mutations detected in these samples were 3.29% for CYP2D6*3, 20.00% for CYP2D6*4, 3.70% for CYP2D6*5, 1.37% for CYP2D6*6 and 0.14% for CYP2D6*7 and CYP2D6*15. All genotype frequencies fulfilled the Hardy-Weinberg Equilibrium expectation (Table 3) . It is noteworthy that CYP2D6*3 is the third most common loss of function mutation in this cohort. 
Discussion
The value of individualized drug therapy is continuously being recognized by regulatory authorities [19, 20] . As such, scientists in the field of pharmacogenomics (PGx), as well as physicians and analytical laboratory staff, are constantly searching for efficient and affordable methodologies to genotype patients. Furthermore, both commercial and private entities are continuously designing and validating these very types of techniques. However, limitations exist with every methodology, despite the cost, robustness or extent of validation. One limitation of genotyping, no matter the method used, includes allele drop out events, due to the presence of variations besides the one of interest. These events have been described for genotyping assays across multiple genes [14, 15, [21] [22] [23] [24] . While the majority of these interfering variations are usually rare, they can severely alter accurate prediction of the metabolizing phenotype within a particular individual. As there is no clear governance regarding how many methodologies analytical laboratories are required to perform for a given genetic variation, it is conceivable that there are apparent gaps between genotype and predicted phenotype that consequently hamper PGx guided therapy [8] .
Individuals are currently classified into CYP2D6 metabolizing activity categories based on their genotype. The number of categories and the genotypes that belong to each category vary between PGx expert groups. Recently published data from Caudle et al. regarding the standardization of terms for clinical PGx test results described five CYP2D6 metabolizing phenotype categories: ultrarapid (increased activity compared to rapid metabolizers), rapid (activity between that of ultrarapid and normal metabolizers), normal (fully functional activity), intermediate (activity between that of normal and poor metabolizers) and poor (little to no enzyme activity) [25] . Sample #7 was found to have a CYP2D6 genotype of *3/*41. The CYP2D6*3 variant causes a frameshift at p.Arg259 that results in a CYP2D6 protein with little to no function [26, 27] . CYP2D6*41 alleles are reported to produce decrease of function proteins [28, 29] . This genotype would predict an intermediate (to normal) CYP2D6 [30] . We have shown that the CYP2D6 g.2470T>C variant interferes with two CYP2D6*3 genotyping assays-a hydrolysis probe assay from Thermo and a previously described pyrosequencing assay [17] . The CYP2D6 g.2470T>C results in complete allele-drop out in the hydrolysis probe assay from a leading provider, and causes a substantial amplification bias in the pyrosequencing assay described by Langaee et al [17] . It is important to underline that this variant, with an occurance of 2.47%, is not rare. The allele frequency of CYP2D6*3 is 3.29%. Therefore, the percentage of the population that are expected to harbour the same genotype as sample #7 is ~0.08%. While this percentage seems quite small, its magnitude can be better appreciated in the context of the actual number of individuals in the population. All samples were obtained from self-proclaimed Caucasians of European descent. Assuming a European population of ~500 million, the estimated number of individuals with the same genotype as sample #7 is ~400, 000.
Re-design of both assays to avoid g.2470T>C solved the allele drop out. Information regarding allele drop out events in the context of PGx testing is valuable for all those that are involved in developing and/or performing these types of analytics, as well as the patients whose drug therapy may be altered by PGx results. Verification of results with two separate methodologies may help to clarify allele drop out events. In cases where two different methodologies cannot be used, those assays that have been documented to avoid known causes of miscalls will help to increase the quality of PGx analytics as well as its implementation.
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